InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC
InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro.
Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs. The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC.
Anti-fibrotic therapies aim to inhibit activation of hepatic stellate cell (HSCs), thereby preventing excessive accumulation of extracellular matrix (ECM) proteins, such as collagen, which can lead to cirrhosis and liver failure. The InSphero 3D InSight(TM) Human Liver Fibrosis Model is unique in that it contains all liver cell types necessary to mimic fibrosis in vitro in a high throughput, screening-compatible platform.
InSphero Chief Scientific Officer Dr. Patrick Guye says, "Our 3D human fibrosis model is composed of primary human liver cells, including HSCs, hepatocytes, Kupffer cells, and liver endothelial cells, all of which are required to accurately reflect the clinical fibrotic disease state in a cell culture model. Treatment of the model with TGF-b1, a known inducer of HSC activation, was shown to trigger strong induction of pro-fibrotic gene expression and ECM protein accumulation in the microtissue, resulting in collagen deposition and diminished hepatocyte function, both hallmarks of liver fibrosis. Even more promising, we were clearly able to demonstrate successful inhibition of disease progression on a phenotypic and transcriptional level using drugs known to interfere with pro-fibrotic signalling pathways."
Dr. Jan Lichtenberg, InSphero Chief Executive Officer and Co-founder, notes, "These findings support the power of our model to help drug discovery groups meet the demand for safer, more effective anti-fibrotic drugs. The initial feedback from beta testers within major pharmaceutical groups with fibrosis programs has been overwhelmingly positive. Not only does the model overcome the lack of cellular complexity of current in vitro models, but being based on our pharma-validated Human Liver Microtissue platform, it can deliver valuable data on both the efficacy and safety of drug candidates, without the use of animal models."
AASLD Presentation Details
Friday, October 20: 12:00 - 1:30 PM
Abstract #385: Development and characterization of a novel in vitro human liver fibrosis model for efficacy testing of anti-fibrotic drugs based on 3D Human Liver Microtissues
Poster presented by: Dr. Radina Kostadinova, InSphero AG
For more information about InSphero, visit www.insphero.com.
Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight(TM) Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology. All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.
InSphero 3D InSight(TM) solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies.
Founded in 2009, the privately held company is headquartered in Switzerland, with subsidiaries in the United States and Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1201e5f9-a462-4dca-b453-e61881c14090
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/63584ccd-618f-48fd-aec4-5e289e46c2de
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c0354196-0927-49f8-9fb5-2a57e0e2d025
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InSphero AG via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
PayByPhone appoints Andreas Gruber as new President and CEO20.4.2018 00:19 | Pressemelding
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it will appoint Andreas Gruber as president and Chief Executive Officer effective June 1st, 2018. Francis Dupuis, the former President and CEO, will take over a position in Germany with parent company Volkswagen Financial Services AG. To provide additional impetus to the PayByPhone board, two new board positions have been created and as a result Maggie Clay (CFO) and Catherine Scott (Legal Counsel) will be appointed effective June 1st, 2018. During his time at PayByPhone, Francis led the business through significant growth and organizational change and leaves the company well positioned for continued success. "We would like to thank Francis for his strong leadership and look forward to building on his experience within Volkswagen Financial Services," Gerd Künne, Vice-President of mobility unit at Volkswagen Financial Services, said. Francis is e
Progress and Potential for Achieving Cleaner Air on a Global Basis20.4.2018 00:09 | Pressemelding
Adoption of New Generation Diesel Technology Delivers Rapid Clean Air Benefits New understanding of global air quality highlights the need for technologies like new-generation diesel engines, which are capable of accelerating emissions reductions WASHINGTON, April 19, 2018 (GLOBE NEWSWIRE) -- Recent reports highlighting air quality conditions in the United States (State of the Air) and globally (State of Global Air 2018) celebrate the progress made in developed and developing countries, but also emphasize significant disparities in progress toward reducing levels of key pollutants such as particulate matter and ozone. "Achieving continued clean air progress while also sustaining economic growth is possible. Cities and countries must move to proven cleaner engines and fuels," said Allen Schaeffer, executive director of the Diesel Technology Forum. "We can and should bring the tremendous benefits of new technology diesel engines to communities and countries large and small around the wor
SD-WAN for Office 365: Aryaka Helps eLearning company, City & Guilds Group, Improve Office 365 Application Response Time19.4.2018 18:54 | Pressemelding
Aryaka's Global SD-WAN reduces time for global users to open SharePoint files from 10 to 0.05 seconds; Outlook performance improves 9x worldwide LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today its SD-WAN technology has enabled City & Guilds Group, a worldwide leader in workplace skills, eLearning, and executive coaching, to achieve faster Office 365 application response times leading to an increase in productivity and better collaboration between users in Europe and Asia-Pacific. Headquartered in London, the City & Guilds Group works with education providers, governments and major corporations to help shape and support skills development for employers in over 100 countries. Team members of the company are similarly scattered around the world and primarily collaborate using Microsoft Office 365 applications, but many remote users were struggling to access the group's instance of Office 365 hosted in Dublin. For example, it could ta
Canacol Energy Ltd. Announces Private Offering of Senior Notes19.4.2018 16:23 | Pressemelding
CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE) (OTCQX:CNNEF) (BVC:CNEC) is pleased to announce that it intends, subject to market and other conditions, to offer senior unsecured notes (the "Notes") in a private placement to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), to non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act and pursuant to certain prospectus exemptions in Canada (the "Offering"). The Notes will be fully and unconditionally guaranteed by certain subsidiaries of Canacol. The interest rate, redemption prices and other terms of the Notes are to be determined upon pricing of the Offering. Canacol intends to use the net proceeds from the Offering: (i) to repay the outstanding amounts borrowed under its credit facility; (ii) to pay fees and expenses of the O
Cisco ACI Is Data Center Solution of Choice for Service Providers Worldwide19.4.2018 14:00 | Pressemelding
Service providers deliver new cloud services more quickly and offer superior customer experience with the help of Cisco Application Centric Infrastructure SAN JOSE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Providing secure, differentiated and rapidly delivered cloud services to customers is a crucial requirement for today's service providers. To meet cloud infrastructure demands, global service providers are increasingly turning to the Cisco® Application Centric Infrastructure (Cisco ACI(TM)) , the industry-leading software-defined networking (SDN) solution. Cisco ACI reduces operational costs with an automated, policy-based programmable architecture, while improving scalability and security. In addition, new Cisco ACI multi-site management capability helps service providers to connect and manage multiple geographically distributed Cisco ACI fabrics and to move and manage workloads with a single pane of glass. Cisco ACI is being deployed worldwide by service providers such as NTT Com
SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00 | Pressemelding
SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom